Sopha parent takes MRI effort; stays out of U.S.
Weakness in the global MRI market has prompted gamma camera developerSopha Medical of Buc, France, to withdraw its effort to marketa low-field MRI system in the U.S. Sopha's controlling interest in French MRI developer Magnetechhas been transferred to
Weakness in the global MRI market has prompted gamma camera developerSopha Medical of Buc, France, to withdraw its effort to marketa low-field MRI system in the U.S.
Sopha's controlling interest in French MRI developer Magnetechhas been transferred to parent company CEA-I, which will directMagnetech's product development and marketing, according to SophaMedical Systems vice president of sales Buster Houchins.
Sopha Medical is the parent company of Sopha Medical Systemsof Columbia, MD. The French firm purchased a 51% interest in Magnetechin 1991 (SCAN 5/22/91). Magnetech and the U.S. subsidiary sharedbooth space at last year's Radiological Society of North Americameeting.
Magnetech's 0.1-tesla scanner has been marketed in Europe,and Sopha was considering bringing the unit to the U.S. But ongoingsluggishness in the global MRI market--contrasted with continuedgrowth in nuclear medicine--caused the vendor to scale back itseffort and focus on its core modality.
"It's not an attractive time for a company to enter the(MRI) marketplace," Houchins said.
Sopha transferred its interest to CEA-I this spring, Houchinssaid. CEA-I is the for-profit division of the French government'sAtomic Energy Commission. It acquired a controlling interest inSopha earlier this year (SCAN 4/7/93).
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
